Alpha Tau to present promising head and neck cancer combo therapy data at AHNS 2026 conference

Alpha Tau Medical announced that its clinical trial data on combining Alpha DaRT, a targeted alpha-radiation therapy, with pembrolizumab for elderly patients with advanced head and neck squamous cell carcinoma will be presented at the AHNS 12th International Conference in July 2026. This combination aims to enhance immune response and improve outcomes for patients who often cannot tolerate aggressive treatments. The trial builds on prior monotherapy studies and highlights Alpha DaRT's safety and potential as an add-on to immunotherapy without increasing toxicity. The presentation marks a key milestone in advancing treatment options for this challenging patient group.